339185-70-5

Basic information

• Product Name: tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate
• Synonyms: tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate;tert-butyl (2-(4-bromophenyl)-2-oxoethyl)carbamate;4-Bromophenacylamine,N-BOCprotected
• CAS NO: 339185-70-5
• Molecular Formula: C₁₃H₁₆BrNO₃
• Molecular Weight: 314.17504
• Mol File: 339185-70-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate(339185-70-5)
• EPA Substance Registry System: tert-Butyl N-[2-(4-bromophenyl)-2-oxoethyl]carbamate(339185-70-5)

Safety Data

• Hazardous Substances Data: 339185-70-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7644-04-4 4-bromophenacylamine 
• 99-73-0 para-bromophenacyl bromide 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 

Downstream Products

• 736989-88-1 1,1-dimethylethyl {2-oxo-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate 
• 1256386-05-6 1,1-dimethylethyl[2-(4'-{2-[(2S)-1-((2S)-3-methyl-2-{[(methyloxy)carbonyl] amino}butanoyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-4-biphenylyl)-2-oxoethyl]carbamate 
• 1272656-19-5 1,1-dimethylethyl 2-{N-[(methyloxy)carbonyl]-L-valyl}-3-(4-{4′-[2-((2S)-1-{N-[(methyloxy)carbonyl]-L-valyl}-2-pyrrolidinyl)-1H-imidazol-4-yl]-4-biphenylyl}-1H-imidazol-2-yl)-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 913181-90-5 tert-butyl (2-(4-bromophenyl)-2-hydroxyethyl)carbamate 
• 1447940-16-0 tert-butyl (1S,1'S)-1,1'-(5,5'-(4,4'-(ethyne-1,2-diyl)bis(4,1-phenylene))bis(1H-imidazole-5,2-diyl))bis(2,2-dimethylpropane-1,1-diyl)dicarbamate 
• 1272657-16-5 methyl [(1S)-2-methyl-1-({(2S)-2-[4-(4′-{2-[1-((2S)-3-methyl-2-{[(methyloxy)carbonyl]amino}butanoyl)-8,8-dioxido-8-thia-1-azaspiro[4.5]dec-2-yl]-1H-imidazol-4-yl}-4-biphenylyl)-1Himidazol-2-yl]-1-pyrrolidinyl}carbonyl)propyl]carbamate 
• 1571137-44-4 benzyl 2-(5-(4′-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1′-biphenyl]-4-yl)-1H-imidazol-2-yl)-8-oxa-1-azaspiro[4.5]decane-1-carboxylate 
• 1272657-14-3 methyl ((1S)-1-{[(2S)-2-(4-{4′-[2-(1-acetyl-8,8-difluoro-1-azaspiro[4.5]dec-2-yl)-1H-imidazol-4-yl]-4-biphenylyl}-1H-imidazol-2-yl)-1-pyrrolidinyl]carbonyl}-2-methylpropyl)-carbamate 
• 1272656-98-0 methyl ((1S)-1-{[(2S)-2-(4-{4′-[2-(1-acetyl-8-oxa-1-azaspiro-[4.5]dec-2-yl)-1H-imidazol-4-yl]-4-biphenylyl}-1H-imidazol-2-yl)-1-pyrrolidinyl]carbonyl}-2-methylpropyl)carbamate 
• 1256388-43-8 methyl {(1S)-1-[((2S)-2-{4-[4′-(aminoacetyl)-4-biphenylyl]-1H-imidazol-2-yl}-1-pyrrolidinyl)carbonyl]-2-methylpropyl}-carbamate 

Relevant articles and documents

Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy

Amphiphilic drug conjugates can self-assemble into nanovehicles for cancer drug delivery, but the key is to design stable yet intracellular labile drug linkers for drug retention during blood circulation but fast intracellular drug release. The conjugatio

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: From lead to clinical compound

Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropyrrolidine motifs in novel NS5A inhibitors and a proposed interaction model. We discovered that the 1,4-dioxa-7-azaspiro[4.4]nonane motif in inhibitor 41H (GSK2236805) supported high potency against genotypes 1a and 1b as well as in genotype 1b L31V and Y93H mutants. Consistent with this, 41H potently suppressed HCV RNA in the 20-day RNA reduction assay. Pharmacokinetic and safety data supported further progression of 41H to the clinic.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

ANTIVIRAL COMPOUNDS

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

CHEMICAL COMPOUNDS

Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.

Biaryl substituted hydantoin compounds as TACE inhibitors

We disclose further optimization of hydantoin TNF-α convertase enzyme (TACE) inhibitors. SAR with respect to the non-prime region of TACE active site was explored. A series of biaryl substituted hydantoin compounds was shown to have sub-nanomolar Ki